CenterBook Partners LP Acquires 616,490 Shares of Clarivate PLC $CLVT

CenterBook Partners LP boosted its holdings in shares of Clarivate PLC (NYSE:CLVT) by 81.8% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,369,972 shares of the company’s stock after purchasing an additional 616,490 shares during the period. CenterBook Partners LP’s holdings in Clarivate were worth $4,576,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in CLVT. Balyasny Asset Management L.P. lifted its stake in Clarivate by 827.6% during the third quarter. Balyasny Asset Management L.P. now owns 4,882,593 shares of the company’s stock worth $18,700,000 after purchasing an additional 4,356,232 shares during the last quarter. Bank of America Corp DE lifted its stake in shares of Clarivate by 506.9% in the 2nd quarter. Bank of America Corp DE now owns 2,870,668 shares of the company’s stock valued at $12,344,000 after acquiring an additional 2,397,670 shares during the last quarter. Man Group plc lifted its stake in shares of Clarivate by 228.1% in the 2nd quarter. Man Group plc now owns 3,091,139 shares of the company’s stock valued at $13,292,000 after acquiring an additional 2,148,943 shares during the last quarter. LSV Asset Management bought a new position in shares of Clarivate in the 3rd quarter valued at $8,072,000. Finally, American Century Companies Inc. lifted its stake in shares of Clarivate by 20.6% in the 3rd quarter. American Century Companies Inc. now owns 9,973,797 shares of the company’s stock valued at $38,200,000 after acquiring an additional 1,706,306 shares during the last quarter. 85.72% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on CLVT. Royal Bank Of Canada dropped their price target on Clarivate from $5.00 to $3.00 and set a “sector perform” rating for the company in a research note on Wednesday, February 25th. Barclays dropped their price target on Clarivate from $4.00 to $2.40 and set an “underweight” rating for the company in a research note on Wednesday, February 25th. Wall Street Zen upgraded Clarivate from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Clarivate in a research note on Friday, March 27th. Finally, Citigroup dropped their price target on Clarivate from $4.25 to $2.80 and set a “neutral” rating for the company in a research note on Wednesday, March 4th. Five analysts have rated the stock with a Hold rating and three have issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Reduce” and an average target price of $3.22.

Clarivate Stock Up 1.0%

Shares of NYSE:CLVT opened at $2.44 on Tuesday. The firm has a market cap of $1.56 billion, a P/E ratio of -11.60 and a beta of 1.37. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 0.89. Clarivate PLC has a 12-month low of $1.66 and a 12-month high of $4.77. The business has a fifty day simple moving average of $2.53 and a 200 day simple moving average of $2.77.

Clarivate (NYSE:CLVT) last announced its earnings results on Wednesday, April 29th. The company reported $0.18 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.14 by $0.04. The business had revenue of $585.50 million during the quarter, compared to analyst estimates of $569.50 million. Clarivate had a positive return on equity of 8.82% and a negative net margin of 5.61%.Clarivate’s revenue for the quarter was down 1.4% compared to the same quarter last year. During the same period last year, the company earned $0.14 EPS. Clarivate has set its FY 2026 guidance at 0.700-0.800 EPS. Analysts predict that Clarivate PLC will post 0.65 earnings per share for the current year.

Clarivate Profile

Clarivate plc is a global information and analytics company that provides insights and workflow solutions to accelerate the pace of innovation. The company delivers proprietary data, analytics, and expertise to support research and development in the life sciences, intellectual property management, academic institutions, government agencies, and corporations. Its core offerings include citation and patent databases, drug pipeline analytics, trademark research tools, regulatory compliance solutions, and market intelligence platforms.

Originally part of Thomson Reuters’ Intellectual Property & Science division, Clarivate was established as an independent entity in 2016 following a spin-off transaction.